for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

Allergan settles generic Asacol delay claims for nearly $2.75 million

Allergan PLC has agreed to pay nearly $2.75 million to three union-sponsored health benefit plans to resolve a lawsuit alleging that a drugmaker the company now owns suppressed generic competition for its ulcerative colitis drug Asacol.

The settlements were disclosed in federal court in Boston on Friday, a day after an appellate court rejected the plaintiffs’ effort to challenge a judge’s decision to not consider their latest request to certify a class of purchasers of the drug.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2YF0QZz

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up